Business
Viridian Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
Completed a successful pre-IND meeting with the FDA for VRDN-001, a differentiated monoclonal antibody targeting IGF-1R for the treatment of Thyroid Eye
About this update from Viridian Therapeutics, Inc.
[{"type":"text","content":"Completed a successful pre-IND meeting with the FDA for VRDN-001, a differentiated monoclonal antibody targeting IGF-1R for the treatment of Thyroid Eye Disease On track to submit an IND filing with the FDA for VRDN-001 in the fourth quarter of 2021 and for key proof of concept clinical data in Thyroid Eye Disease patients in the second quarter of 2022First VRDN-001 clinical trial data has potential to show rapid and substantial reduction in proptosis, the defining symptom of Thyroid Eye Disease Multiple abstracts accepted for upcoming presentation at the American Thyroid Association (ATA) Annual Meeting, highlighting preclinical data for Viridian’s differentiated IGF-1R antibodiesStrengthened management team with appointments of Kristian Humer as Chief Financial Officer and Chief Business Officer and Deepa Rajagopalan, M.D. as SVP of New Product and Portfolio DevelopmentReported $109 million in cash, cash equivalents and short-term investments as of June 30, 2021, providing cash runway into 2024 WALTHAM, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “Company” or “Viridian”), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases and underserved by current therapies, today announced financial results for the second quarter ended June 30, 2021, and provided corporate updates. “We continue to make rapid progress with our lead TED program, VRDN-001,” said Jonathan Violin, Ph.D., President and Chief Executive Officer of Viridian. “Following a highly collaborative pre-IND dialogue with the FDA for VRDN-001, we remain on track to submit IND filings for both VRDN-001 and VRDN-002 to the FDA in the fourth quarter of 2021. This would put us on track to report key Phase 1/ 2 proof of concept clinical data in TED patients in the second quarter of 2022 for VRDN-001, quickly followed by Phase 1 first-in-human data in mid-year 2022 for VRDN-002. We are also progressing our discovery programs as we expand our pipeline beyond IGF-1R and TED, advancing our strategy to discover and develop novel and differentiated monoclonal antibodies.” Second Quarter 2021 and Recent Highlights VRDN-001: Viridian’s most advanced product candidate is VRDN-001, a differentiated monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commerci...